BPC-157 vs TB-500: Lab Research Comparison

BPC-157 vs TB-500: Laboratory Research Comparison
By the Zen Well Labs Research Team · Last reviewed September 2026 · For laboratory research reference only

Short answer: BPC-157 and TB-500 are different research peptides with different sequences, masses and literature themes. BPC-157 is a synthetic 15-residue fragment (GEPPPGKPADDAGLV; ≈1419.5 Da; CAS 137525-51-0) studied mainly in rodent and cell-culture models of tissue and gastrointestinal endpoints. “TB-500” is a trade name that vendors apply either to full-length thymosin beta-4 (43 residues, ≈4963.5 Da, CAS 77591-33-4) or to a short Ac-LKKTETQ actin-binding fragment (≈889 Da). They are not interchangeable reagents. Both are sold by Zen Well Labs for in-vitro laboratory research only; neither is FDA-approved for any use. This page compares identity data and published research themes — it does not describe protocols for administration to humans or animals.

| — | — | — | — |

| Molecular weight | ≈1419.5 Da | ≈4963.5 Da | ≈889 Da |

| CAS | 137525-51-0 | 77591-33-4 | No single widely cited CAS for the fragment alone |

| Best-known research theme | Preclinical GI, tendon/ligament cell and angiogenesis models | G-actin sequestration; cell motility; wound and cardiac injury models | Actin-binding motif fragment studies; anti-doping detection literature |

Always confirm the mass on the Certificate of Analysis. A vial labelled “TB-500” that reads ~889 Da is not the same material as one that reads ~4963 Da. See What is BPC-157? and What is TB-500? for compound-level detail.

Identity first: why the comparison fails if the vial is wrong
Comparison pages are only useful when both reagents are chemically defined. For BPC-157 that is straightforward: one sequence, one CAS, one theoretical mass. For TB-500 it is not. Anti-doping and veterinary history popularised the short Ac-LKKTETQ fragment under the TB-500 name; many research-chemical suppliers later applied the same name to full-length synthetic thymosin beta-4. The two differ more than five-fold in mass, so milligram-for-milligram molar concentrations diverge sharply, and literature on full-length Tβ4 cannot be assumed to apply to the fragment.

Practical identity checks before any head-to-head experiment:

1. Read the MS line on each COA.
2. Match BPC-157 to ≈1419.5 Da and CAS 137525-51-0.
3. Match Zen Well Labs TB-500 to ≈4963.5 Da and CAS 77591-33-4 (full-length Tβ4).
4. Reject ambiguous “TB-500” lots that cannot state which molecule they contain.
Our guide on how to read a peptide COA covers the fields that settle these questions.

Structural and biochemical differences
BPC-157 is a linear, all-proteinogenic-residue peptide derived from a larger gastric “Body Protection Compound” described by University of Zagreb researchers. The 15-residue fragment sold for research is fully synthetic. Early papers emphasised unusual stability of the fragment in gastric-juice incubations in vitro — hence the recurring phrase “stable gastric pentadecapeptide” in that literature.

Thymosin beta-4 is a highly conserved intracellular polypeptide whose best-characterised biochemical role is sequestering G-actin monomers (Safer, Elzinga & Nachmias, Journal of Biological Chemistry, 1991). Actin binding maps in part to the central LKKTETQ motif; the synthetic Ac-LKKTETQ fragment isolates that motif. Full-length Tβ4 also contains a methionine residue, which is a practical oxidation-sensitive site during laboratory storage.

These are different molecular classes: a short synthetic gastric-derived fragment versus a cytoskeletal regulatory protein (or a seven-residue slice of it). There is no shared receptor, no shared sequence homology of note, and no reason to treat them as “versions” of one another.

What published research has looked at (themes, not protocols)
The sections below summarise literature themes that appear in peer-reviewed preclinical work. They are not instructions for use, not claims of human benefit, and not a suggestion to combine the two reagents outside a defined research hypothesis.

BPC-157 literature themes
Nearly all BPC-157 papers are preclinical — rodent models and cell culture — with a large share from a single research group (Sikiric and colleagues, Zagreb). Reported themes include:

Tendon and ligament fibroblast models (for example Chang et al., Journal of Applied Physiology, 2011, on rat tendon fibroblast outgrowth, survival and migration).
Angiogenesis-related signalling (VEGFR2 / Akt–eNOS pathways in endothelial and rodent models).
Interactions with nitric oxide system agonists and antagonists in rodent models.
Gastrointestinal lesion models in rodents (reviewed in Current Pharmaceutical Design, 2011).
What is missing: large, peer-reviewed randomized controlled trials establishing human safety or efficacy; FDA approval for any indication.

TB-500 / thymosin beta-4 literature themes
Full-length Tβ4 has a broader and more diverse peer-reviewed literature, reviewed for example by Goldstein, Hannappel and Kleinman (Trends in Molecular Medicine, 2005). Themes include:

Actin dynamics and cell migration.
Angiogenesis endpoints in endothelial models.
Corneal and dermal wound models.
Cardiac injury models in rodents.
Sosne and colleagues (FASEB Journal, 2010) summarised how different short segments of Tβ4, including the actin-binding motif, map to different activities in cell and animal models — which is exactly why the fragment and the full-length protein must not be conflated. Recombinant or synthetic Tβ4 has entered early-phase clinical investigation for specific indications in the broader pharmaceutical literature, but no TB-500 research-chemical product and no BPC-157 product is FDA-approved.

Overlap that is only superficial
Both peptide names appear in online discussions of “repair” or “recovery.” That consumer framing is not a scientific identity. In the laboratory, overlap is limited to the broad observation that each molecule has been studied in models involving cell motility, matrix or vascular endpoints — through different proposed mechanisms and with different levels of independent replication. A responsible comparison stops at that level and does not invent shared clinical indications.

Experimental design notes for laboratory comparison studies
When a protocol genuinely requires both reagents as defined analytical or cell-culture tools:

Normalise by moles, not milligrams, especially if one arm uses full-length Tβ4 (~4963 Da) and the other uses BPC-157 (~1419 Da).
State which TB-500 species (full-length vs Ac-LKKTETQ) in the methods section; cite the COA mass.
Do not borrow endpoints from one literature onto the other without a mechanistic hypothesis (actin sequestration endpoints are Tβ4-native; gastric-stability narratives are BPC-157-native).
Control for vehicle and salt form; both are typically supplied as lyophilized acetate or related salts.
Keep the work in vitro or under approved animal-care protocols as required by your institution. Zen Well Labs materials are not for human or veterinary administration.
Storage and handling side by side
Both lyophilized peptides are generally stored sealed, dry and dark at −20 °C. After reconstitution, aliquot to avoid freeze–thaw and keep working solutions at 2–8 °C within a window supported by your own stability data. Tβ4’s methionine makes oxidation control more important for that reagent; protect from unnecessary air exposure. Shared guidance: lyophilized peptide storage and stability and bacteriostatic water vs sterile water.

| — | — | — | — |

| MS identity | ≈1419.5 Da | ≈4963.5 Da | ≈889 Da |

| CAS on paperwork | 137525-51-0 | 77591-33-4 | Often omitted — require mass |

If paperwork cannot distinguish the TB-500 species, do not use that lot as a defined comparator to BPC-157.

Frequently asked questions
Are BPC-157 and TB-500 the same peptide?
No. They have different lengths, sequences, masses and literature bases. BPC-157 is a 15-residue synthetic peptide; TB-500 is a trade name for either full-length thymosin beta-4 or a 7-residue fragment.

Which one has more published research?
Full-length thymosin beta-4 has a broader, multi-group literature spanning actin biology and tissue models. BPC-157 has an extensive but more concentrated preclinical literature, much of it from one research network. Volume of papers is not the same as regulatory approval.

Can the two be compared head-to-head in vitro?
Yes, as chemically defined research tools, provided each lot’s identity is confirmed by mass and the experimental endpoints are chosen for a clear mechanistic reason. That is a laboratory design question, not a use recommendation.

Is either FDA-approved?
No. Neither BPC-157 nor TB-500 / thymosin beta-4 research-chemical products are FDA-approved for any use. Both names appear in anti-doping prohibited-substance contexts.

What does Zen Well Labs sell each as?
BPC-157 is the defined 15-residue peptide (CAS 137525-51-0). TB-500 is specified as full-length thymosin beta-4 (CAS 77591-33-4, ≈4963.5 Da). Both are for in-vitro laboratory research only.

References
Sikiric P, et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Current Pharmaceutical Design. 2011;17(16):1612–1632.
Chang CH, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. Journal of Applied Physiology. 2011;110(3):774–780.
Safer D, Elzinga M, Nachmias VT. Thymosin beta 4 and Fx, an actin-sequestering peptide, are indistinguishable. Journal of Biological Chemistry. 1991;266(7):4029–4032.
Goldstein AL, Hannappel E, Kleinman HK. Thymosin beta4: actin-sequestering protein moonlights to repair injured tissues. Trends in Molecular Medicine. 2005;11(9):421–429.
Sosne G, Qiu P, Goldstein AL, Wheater M. Biological activities of thymosin beta4 defined by active sites in short peptide sequences. FASEB Journal. 2010;24(7):2144–2151.
PubChem Compound Summary, CID 9941957 (BPC-157). National Center for Biotechnology Information.
World Anti-Doping Agency. Prohibited List.
Related
What is BPC-157?
What is TB-500?
How to read a peptide COA
Lyophilized peptide storage and stability
Research use only. All products sold by Zen Well Labs are intended strictly for in-vitro laboratory research. They are not drugs, foods, cosmetics or dietary supplements, are not approved by the FDA for any use, and are not for human or veterinary use. Nothing on this page is medical advice, and nothing here describes or recommends administration to humans or animals.

BPC-157 vs TB-500: Lab Research Comparison

Leave a Reply Cancel reply

Researcher Verification